<DOC>
	<DOCNO>NCT01257581</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy high dose creatine two dosage tamoxifen treatment amyotrophic lateral sclerosis ( ALS ) .</brief_summary>
	<brief_title>Safety Efficacy Study Creatine Tamoxifen Volunteers With Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description>Amyotrophic lateral sclerosis ( ALS ) rare , neurodegenerative disorder result progressive waste paralysis voluntary muscle . It know nerve cell call motor neuron die brain spinal cord people amyotrophic lateral sclerosis ( ALS ) . However , cause cell death unknown . In double blind , randomize , selection design trial , researcher evaluate safety effectiveness creatine tamoxifen volunteer ALS . There large number potential drug may improve survival slow disease progression people ALS . The current strategy test one drug time placebo . `` Selection Design '' different type study design . A Selection Design study use multiple drug screen pick winner take large study . This design speed search effective drug treat ALS . In Selection Design study , volunteer take one active study drug ( creatine 30gm , tamoxifen 40mg , tamoxifen 80mg ) one placebo . Approximately 60 eligible volunteer ALS recruit multiple center US belong Northeast ALS Consortium ( NEALS ) . Volunteers randomly assign equally three treatment arm : creatine 30gm/day , tamoxifen 40mg/day tamoxifen 80mg/day . Volunteers take study treatment 38 week . After screen randomization , volunteer follow week 4 , 10 , 18 , 28 week 38 . A final telephone interview occur week 42 ( study drug ) .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Familial sporadic ALS . Disease duration diagnosis great 36 month Screening Visit . Aged 18 year old . Capable provide informed consent comply trial procedure . Vital capacity ( VC ) equal 50 % predict normal value gender , height age Screening Visit . Not take , stable dose riluzole ( 50mg bid ) least 30 day prior Screening Visit . Women must able become pregnant duration study ( e.g. , post menopausal least one year , surgically sterile , practice adequate birth control method ) duration study . Women childbearing potential must negative serum pregnancy test Screening Visit nonlactating . History known sensitivity intolerability creatine monohydrate tamoxifen citrate relate compound . Prior exposure creatine tamoxifen within 30 day Screening Visit . Exposure investigational agent within 30 day Screening Visit . Use coumarin anticoagulant ( warfarin sodium ) , rifampin , aminoglutethimide , medroxyprogesterone , letrozole , bromocriptine . Presence follow clinical condition : Clinical evidence unstable medical psychiatric illness Screening Visit ; Screening aspartate aminotransferase ( AST ) &gt; 3 time upper limit normal serum creatinine &gt; 1.5 mg/dl ( 133 umol/L ) ; Permanent assist ventilation mechanical ventilation ; Lactating positive serum pregnancy test Screening Visit . History follow : blood clot include deep vein thrombosis , pulmonary embolism , stroke , cataract , renal problem , endometrial cancer , uterine sarcoma , diabetes mellitus .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>ALS</keyword>
	<keyword>Lou Gehrig 's Disease</keyword>
	<keyword>Amyotrophic Lateral Sclerosis</keyword>
	<keyword>Creatine</keyword>
	<keyword>Tamoxifen</keyword>
	<keyword>Selection Design</keyword>
</DOC>